Articles tagged with Parkinsons Disease
A Rutgers University researcher found that dopamine loss causes brain connections to reorganize, leading to impaired motor control. The study suggests that this permanent change may explain why current treatments fail to restore complex movements in Parkinson's disease patients.
The National Institute of Environmental Health Sciences (NIEHS) is launching a $20 million effort to pinpoint environmental triggers of Parkinson's disease. Three centers will conduct independent research, including the University of California at Los Angeles, Emory University, and The Parkinson's Institute.
Emory University will lead a new center studying the relationship between environmental agents and Parkinson's disease, with research focusing on pesticides, organochlorine insecticides, and genetic causes of PD. The center aims to develop strategies for prevention and treatment.
A new Medicines Information Helpline has been launched in the UK to provide independent expert advice on medicines for patients with Parkinson's disease. The helpline, staffed by experienced pharmacists, aims to address the need for reliable information on medication management for this growing population.
Despite expected global warming impacts, a NASA study reveals an increase in Antarctic sea ice coverage, with the area lengthening by at least one day per year spanning around 5.6 million square kilometers.
A study by the American Academy of Neurology found that individuals with depression are more likely to develop Parkinson's disease than those without depression. The researchers suggest that low levels of serotonin in the brain may contribute to both depression and Parkinson's disease, increasing the risk of developing the latter.
Computer model simulates brain cell firing patterns to explain Parkinson's tremors. The model suggests that a synchronized pattern of signals, rather than just increased frequency, is responsible for the characteristic tremors of the disease.
Researchers found significant loss of sympathetic nerve endings in patients with Parkinson's disease (PD), even those without orthostatic hypotension. The study suggests that PD is caused by widespread sympathetic nerve damage, unrelated to treatment with levodopa.
Researchers found that Parkinson's patients who developed dementia had a significantly higher risk of death, regardless of hallucination or depression status. The study also revealed that incident dementia and disease severity were independently associated with an increased risk of mortality.
A study by American Academy of Neurology found that rivastigmine significantly reduced hallucinations and improved cognitive abilities in Parkinson's patients. The medication also showed benefits in reaction times, attention, and caregiver distress.
A study of 32 patients with advanced Parkinson's disease found that fetal cell transplants improved symptoms, with the effects being directly proportional to the results experienced prior to transplant. The transplants also showed a significant improvement in dopamine activity in the brain, which stabilized over time.
A Phase I trial has shown that retinal cell implantation can improve motor function in advanced Parkinson's disease patients by nearly 50 percent, according to researchers at Emory University. The implanted cells provide a source of increased dopamine production, helping to alleviate symptoms such as tremors and stiffness.
Researchers at Emory University Health Sciences Center have found a potential link between low testosterone levels and non-motor symptoms of Parkinson's disease in men. Testosterone replacement therapy showed significant improvement in patients with refractory symptoms, including fatigue, depression, anxiety, and decreased libido.
A study found that green tea extract polyphenol can block the uptake of dopamine, providing a potential protective mechanism against Parkinson's disease. The results suggest that polyphenol can inhibit the uptake of dopamine or neurotoxin MPP+ by blocking dopamine transporter.
A study led by Kenneth Marek found that pramipexole slows dopaminergic neuronal degeneration compared to levodopa in early Parkinson's patients. Most patients will be treated with both medications, and further research is needed to assess the clinical impact of these findings.
Researchers successfully treated rats with chemical-induced Parkinson's disease using gene therapy, restoring normal limb movement. The treatment involves delivering two corrective genes into a specific brain region to prime the production of dopamine, which coordinates limb movements.
Despite being a significant advancement in Parkinson's disease treatment, only 7% of eligible patients in G5 European countries have received deep brain stimulation therapy. Inconsistent funding support and low awareness among general practitioners are major barriers to access.
The Michael J. Fox Foundation awards a $10 million grant to Jeffrey Kordower, PhD, of Rush University Medical Center, to develop embryonic stem cell lines for Parkinson's disease treatment. The goal is to create dopaminergic cells that can be used in research and potentially lead to new treatments.
Two women with Parkinson's disease experienced hair loss while on dopamine agonists pramipexole and ropinirole. After discontinuing these medications and switching to new treatments, their hair growth resumed in both cases.
Researchers at Duke University Medical Center have identified chromosomal regions linked to the age at onset of Alzheimer's and Parkinson's diseases. The study found evidence for age-at-onset genes on chromosomes 10, 1, 4, and 8, which could lead to new avenues of research to delay disease onset.
Researchers found that mice fed a folate-deficient diet developed severe Parkinson-like symptoms, while those with adequate amounts of the vitamin protected their brain cells from damage. Folate deficiency may contribute to increased toxin-induced damage to dopamine-producing neurons.
The American Academy of Neurology has reviewed new drugs for treating Parkinson's disease, but found that they do not offer significant advantages over existing treatments. Current treatment guidelines remain unchanged, emphasizing the importance of individualized treatment decisions.
A team of Penn researchers found that molecular chaperones can block the progression of neurodegenerative diseases like Parkinson's by preventing neuronal decay in Drosophila melanogaster. The study suggests that activating these molecules may be an effective approach to treating several human neurodegenerative diseases.
The largest clinical trial ever of Parkinson's disease will be conducted by Professor Karl Kieburtz, with over 3,000 patients participating from 42 sites across North America. The five-year study aims to test the effectiveness of various substances in slowing disease progression.
A protective protein called a chaperone suppresses the toxicity of alpha-synuclein, a protein associated with Parkinson's disease. The study found that augmenting levels of Hsp70 corrected the deficit and overcame the toxic effect of loss of chaperone function.
A study published in Neurology found that electrical brain stimulation increased 'on' motor function by 29 percent and improved 'off' motor function by 38 percent in Parkinson's patients. The treatment reduced the severity of fluctuations in motor symptoms, allowing patients to complete tasks faster and improve their overall mobility.
A study led by Dr. Jeffery M. Vance found significant evidence of linkage between the tau gene and late-onset Parkinson's in three single nucleotide polymorphisms. The research suggests that normal variations in the tau protein may make individuals more susceptible to the disease.
The study provides strong evidence that several genes influence the development of late-onset Parkinson's and that age at onset and response to levodopa may be useful discriminators for genetic origins. Researchers detected evidence for genetic linkage to five distinct regions on chromosomes 5, 6, 8, 9, and 17.
Researchers at UCSD suggest that naturally occurring molecules called beta-synucleins (b-synucleins) may inhibit the excessive accumulation of Lewy bodies, which are characteristic of Parkinson's disease. In mice studies, b-synuclein was shown to block the formation of these abnormal deposits.
Hopkins researchers found that parkin, aS and synphilin interact, with mutations disturbing this interaction leading to Lewy body formation and nerve cell death. Understanding these interactions may help identify targets for new treatments.
A new NASA study found that the Icelandic low-pressure system affects Arctic sea ice cover, leading to regional variations and an overall decrease in ice extent. The system brings warm air northward, reducing ice cover east of Iceland, while also contributing to climate warming.
Scientists discovered that Alzheimer's and Parkinson's proteins interact to accelerate disease progression, causing cognitive and motor function destruction. The study found that Abeta, a metabolic breakdown product of hAPP, enhances the accumulation of hSYN in brain cells.
Researchers at the Mayo Clinic found a possible link between estrogen and reduced risk of Parkinson's disease. The study reviewed medical records of female patients with Parkinson's disease to examine the association with menopause type, age, and postmenopausal hormone therapy.
A new study reveals that many Parkinson's patients are using alternative therapies, despite a lack of physician knowledge on the topic. The research found no correlation between disease severity and use of alternative therapies, suggesting that patients are seeking these treatments for other reasons.
A study found that younger and more educated Parkinson's patients are more likely to use alternative treatments such as vitamins and acupuncture. These patients are also more likely to be married and have developed the disease at a younger age.
Researchers at Virginia Tech are developing a 'prodrug' to deliver neuroprotective compounds to the brain, overcoming limited solubility issues. The approach aims to inhibit monoamine oxidases and neuronal nitric oxide synthase enzymes involved in Parkinson's disease.
Men with constipation were nearly three times as likely to develop Parkinson's disease over the next 24 years compared to those without constipation. The study suggests a potential link between bowel movement frequency and the risk of developing Parkinson's, highlighting the importance of understanding how the disease progresses.
A new skin patch has shown effective treatment of Parkinson's disease in a large-scale study. Patients who received the medication improved their motor skills by an average of 20-30% compared to those who received a placebo.
A study published by researchers at the University of Chicago Medical Center found that prenatal exposure to methamphetamine increases the risk of brain disorders, such as Parkinson's disease, in male offspring who later take the drug themselves. The toxic effects of methamphetamine can hasten the onset of these conditions.
Researchers found that pramipexole prevented nearly 100% of brain cells from dying in mice with a Parkinson's-like condition. The drug also showed neurotrophic effects by increasing dopamine cell size, suggesting potential as a neuroprotective agent.
A study of 15 professional welders found they developed typical clinical signs of Parkinson's disease 15 years earlier than the general population. Brain imaging scans revealed no significant difference in dopamine levels between the welders and control patients, suggesting a possible environmental link.
Scientists have found a link between the combination of two widely used agricultural pesticides and Parkinson's disease in mice. The study, led by Deborah Cory-Slechta, suggests that everyday environmental factors may play a role in the development of the disease.
A new study published in Neurology found that selegiline, a drug used to treat Parkinson's disease, does not increase the risk of death for patients taking levodopa. The study compared the death rates of 97 patients with Parkinson's who received selegiline treatment with those of 902 people without the disease.
A study of 196 people with and without Parkinson's disease found that coffee use was associated with a lower risk of developing the disease. Heavier coffee drinkers exhibited fewer instances of the disease, while tobacco chewers and alcoholics were also less likely to develop the condition.
A recent study found that men are twice as likely to develop Parkinson's disease compared to women. The risk of developing the disease increases with age for both men and women. Researchers are still unsure why Parkinson's is more common in men, but one theory suggests that estrogen may protect women from the disease.
Researchers found that alpha-synuclein, a key component of Parkinson's lesions, is targeted by oxidative stress, specifically nitration. This discovery provides conclusive evidence for the role of oxidative damage in neurodegenerative diseases like Parkinson's and Alzheimer's.
Researchers used gene therapy to deliver GDNF directly to the brain cells of monkeys, resulting in a dramatic increase in dopamine production and prevention of disease progression. The treatment also reversed functional deficits and symptoms associated with Parkinson's disease.
Researchers found that up to 96% of Parkinson's patients experience serious sleep disturbances, often overlooked by doctors. A new study suggests that cabergoline, a long-acting dopamine agonist, offers significant benefits in improving symptoms of sleep disturbance and daytime sleepiness.
A new study published in JAMA found that initiating therapy with MIRAPEX delayed the onset of motor complications and reduced their incidence compared to patients on initial treatment with levodopa. At two years, 72% of MIRAPEX-treated patients were free from motor complications.
Researchers found that pramipexole, a dopamine agonist, reduces debilitating complications in Parkinson's patients. However, it may not control disease symptoms as well as levodopa, which carries more side effects.
Italian researchers found that workers exposed to hydrocarbon solvents, such as petroleum-based products, were three years younger when first showing symptoms. The severity of Parkinson's disease was directly related to the amount of exposure experienced.
A new study reveals Parkinson's disease is associated with a loss of norepinephrine-producing nerve endings in the heart, improving understanding of the disorder's development and potential prevention. This finding also sheds light on orthostatic hypotension, a common complication characterized by dizziness and fainting.
Researchers have identified a compound in tobacco that inhibits an enzyme that breaks down key brain chemicals, potentially offering protection against Parkinson's disease. The discovery opens up new avenues of research and may lead to the development of neuroprotective compounds.
ReQuip significantly reduces the risk of levodopa-induced dyskinesia in Parkinson's disease patients. The five-year study shows that ReQuip monotherapy can reduce dyskinesia incidence by seven times and effectively control early PD symptoms.
A study published in The New England Journal of Medicine confirms Requip's efficacy in managing early Parkinson's disease symptoms with a low risk of developing dyskinesias. Patients taking Requip alone were seven times more likely to remain dyskinesia-free than those on levodopa alone.
Researchers found that people exposed to pesticides were approximately two times more likely to develop Parkinson's disease than those not exposed. In-home exposure to insecticides carried the highest risk of developing the disease.
A study by Emory University neurologists found that pallidotomy surgery significantly improves motor function in patients with Parkinson's disease, with persistent benefits extending to both sides of the body. The long-term effectiveness of this treatment has been confirmed through a 36-month follow-up.
Researchers found a link between smoking, coffee consumption, and lower Parkinson's disease incidence. Higher dopamine levels in the brain may explain why people with these habits are less likely to develop Parkinson's.
Researchers have discovered that synuclein plays a crucial role in communication between neurons, potentially shedding light on the mechanisms underlying Parkinson's and Alzheimer's diseases. The study provides strong evidence that synucleins control the release of neurotransmitters from nerve cells.
Scientists have identified a tobacco compound that may explain why smokers are less vulnerable to Parkinson's disease. The naphthoquinone derivative works by interfering with an enzyme in the brain that breaks down neurotransmitters.